12th Feb 2015 09:17
LONDON (Alliance News) - Silence Therapeutics PLC said Thursday that its ribonucleic acid interference trigger modification patent was upheld by the European Patent Office's board of appeal, against challenges from Alnylam Pharmaceuticals Inc, its subsidiary Sirna Therapeutics Inc, Alcon Laboratories Inc, and an independent attorney.
The company said it has already been granted equivalent patents in the US, China, Israel, India, Japan, Korea and Mexico. It is "vigorously pursuing" further patent applications on both triggers and delivery to fully protect its innovations, it said.
"This is a very important victory for Silence Therapeutics and it strengthens our already broad IP portfolio covering both RNAi triggers and delivery," said Chief Executive Officer Ali Mortazavi in a statement. "We will protect our position robustly whilst always ready to engage in licensing discussions."
Shares in Silence are trading up 2.2% at 230.00 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L